Estrella Immunopharma (ESLA) Cash from Operations (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Cash from Operations of 6700000.0 for Q1 2026, down 1337.83% year-over-year from 541271.17 in Q1 2025, and down 3393.08% quarter-over-quarter from 191808.0 in Q4 2025.
Estrella Immunopharma (ESLA) Cash from Operations (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Cash from Operations for 6 consecutive years, with 6700000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 1337.83% year-over-year to 6700000.0; the TTM figure through Mar 2026 stood at 8034019.0 (up 45.9% YoY), while the FY2025 annual figure was 1800000.0, up 76.44% from the prior year.
- Cash from Operations fell to 6700000.0 in Q1 2026 per ESLA's latest filing, from 191808.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 157144.0 in Q1 2022 and bottomed at 6743607.0 in Q3 2024.
- Historically, Cash from Operations has averaged 2157185.47 across 5 years, with a median of 1100226.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 19087.3% — and 2025, when it soared 93.84%.
- Estrella Immunopharma's Cash from Operations stood at 1208422.0 in 2022, then tumbled by 297.09% to 4798552.0 in 2023, then surged by 35.12% to 3113526.0 in 2024, then jumped by 93.84% to 191808.0 in 2025, then sank by 3393.08% to 6700000.0 in 2026.
- Business Quant data shows ESLA's Cash from Operations at 6700000.0 in Q1 2026, 191808.0 in Q4 2025, and 727332.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.80 Mn |
| Jun 30, 2026 | -1.80 Mn |
| Mar 31, 2026 | -6.70 Mn |
| Mar 31, 2026 | -6.70 Mn |
| Dec 31, 2025 | -191,808.00 |
| Dec 31, 2025 | -191,808.00 |
| Sep 30, 2025 | -727,332.00 |
| Sep 30, 2025 | -727,332.00 |
| Jun 30, 2025 | -414,879.00 |
| Jun 30, 2025 | -414,879.00 |
| Mar 31, 2025 | -465,981.00 |
| Mar 31, 2025 | -465,981.00 |
| Dec 31, 2024 | -3.11 Mn |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.23 Mn |
| Mar 31, 2024 | -4.23 Mn |